BioCentury | Nov 10, 2014
Finance

Imago-in' places

...$26.5 million series A round geared to helping them repeat their performance at hematology play FerroKin BioSciences Inc....
...board. CEO Hugh Rienhoff, who was CEO of FerroKin, formed Imago with other veterans of FerroKin...
...same virtual company model as at FerroKin, and that the idea for Imago came from FerroKin...
BioCentury | Nov 18, 2013
Strategy

Shire goes vertical

...oral metal chelator for transfusional iron overload. SHP602, which Shire gained in its acquisition of FerroKin BioSciences Inc....
...option from Meritage Pharma Inc. SHP602 Metal chelator Transfusional iron overload Ph II Shire; from FerroKin...
BioCentury | Oct 28, 2013
Finance

Paying the iron price

...it paid $100 million up front plus up to $225 million in milestones to acquire Ferrokin BioSciences Inc....
...Bergeron, according to Shiosaki. Bergeron has designed and developed a number of iron chelator analogs. "Ferrokin's...
BioCentury | May 20, 2013
Strategy

Let a thousand ideas bloom

...Shire has an option to license the programs $22M in funding over five years Oct-12 FerroKin BioSciences Inc....
BioCentury | Nov 19, 2012
Strategy

Celgene's venture model

...an equity investment; >$160M in milestones for each licensed program, plus double-digit royalties Preclin Apr-2012 FerroKin BioSciences Inc....
BioCentury | Aug 20, 2012
Company News

FerroKin, Shire deal

...its 1H12 report, Shire said that in April it completed the acquisition of hematology company FerroKin...
...$94.5 million in cash and up to $225 million in milestones (see BioCentury, March 19). FerroKin BioSciences Inc....
BioCentury | Apr 2, 2012
Strategy

Shire's iron backbone

...Strategy Shire's iron backbone By Stephen Hansen Senior Writer Shire plc envisions FBS0701 from FerroKin BioSciences Inc. as...
...commercial hematology unit within its specialty pharmaceuticals business. Last month, Shire said it will acquire FerroKin...
...the cell membrane, allowing for structure-based drug design (see BioCentury, Sept. 15, 2008) . The FerroKin...
BioCentury | Mar 19, 2012
Company News

FerroKin, Shire deal

...Shire will acquire hematology company FerroKin for $100 million up front, plus up to $225 million...
...Factors VII, VIII, IX and X. Seaview Securities advised FerroKin (see BioCentury, Feb. 6). FerroKin BioSciences Inc....
BioCentury | Mar 19, 2012
Finance

Highlights of weekly biotech stock moves

...for Replagal agalsidase alfa to treat Fabry's disease and announcing plans to acquire hematology company FerroKin BioSciences Inc....
BioCentury | Mar 16, 2012
Top Story

Shire to acquire FerroKin for $100M

...Shire plc (LSE:SHP; NASDAQ:SHPGY) will acquire hematology company FerroKin BioSciences Inc. (San Carlos, Calif.) for $100 million up...
...ZFP) therapeutics targeting four genes -- Factors VII, VIII, IX and X. Seaview Securities advised FerroKin...
Items per page:
1 - 10 of 14
BioCentury | Nov 10, 2014
Finance

Imago-in' places

...$26.5 million series A round geared to helping them repeat their performance at hematology play FerroKin BioSciences Inc....
...board. CEO Hugh Rienhoff, who was CEO of FerroKin, formed Imago with other veterans of FerroKin...
...same virtual company model as at FerroKin, and that the idea for Imago came from FerroKin...
BioCentury | Nov 18, 2013
Strategy

Shire goes vertical

...oral metal chelator for transfusional iron overload. SHP602, which Shire gained in its acquisition of FerroKin BioSciences Inc....
...option from Meritage Pharma Inc. SHP602 Metal chelator Transfusional iron overload Ph II Shire; from FerroKin...
BioCentury | Oct 28, 2013
Finance

Paying the iron price

...it paid $100 million up front plus up to $225 million in milestones to acquire Ferrokin BioSciences Inc....
...Bergeron, according to Shiosaki. Bergeron has designed and developed a number of iron chelator analogs. "Ferrokin's...
BioCentury | May 20, 2013
Strategy

Let a thousand ideas bloom

...Shire has an option to license the programs $22M in funding over five years Oct-12 FerroKin BioSciences Inc....
BioCentury | Nov 19, 2012
Strategy

Celgene's venture model

...an equity investment; >$160M in milestones for each licensed program, plus double-digit royalties Preclin Apr-2012 FerroKin BioSciences Inc....
BioCentury | Aug 20, 2012
Company News

FerroKin, Shire deal

...its 1H12 report, Shire said that in April it completed the acquisition of hematology company FerroKin...
...$94.5 million in cash and up to $225 million in milestones (see BioCentury, March 19). FerroKin BioSciences Inc....
BioCentury | Apr 2, 2012
Strategy

Shire's iron backbone

...Strategy Shire's iron backbone By Stephen Hansen Senior Writer Shire plc envisions FBS0701 from FerroKin BioSciences Inc. as...
...commercial hematology unit within its specialty pharmaceuticals business. Last month, Shire said it will acquire FerroKin...
...the cell membrane, allowing for structure-based drug design (see BioCentury, Sept. 15, 2008) . The FerroKin...
BioCentury | Mar 19, 2012
Company News

FerroKin, Shire deal

...Shire will acquire hematology company FerroKin for $100 million up front, plus up to $225 million...
...Factors VII, VIII, IX and X. Seaview Securities advised FerroKin (see BioCentury, Feb. 6). FerroKin BioSciences Inc....
BioCentury | Mar 19, 2012
Finance

Highlights of weekly biotech stock moves

...for Replagal agalsidase alfa to treat Fabry's disease and announcing plans to acquire hematology company FerroKin BioSciences Inc....
BioCentury | Mar 16, 2012
Top Story

Shire to acquire FerroKin for $100M

...Shire plc (LSE:SHP; NASDAQ:SHPGY) will acquire hematology company FerroKin BioSciences Inc. (San Carlos, Calif.) for $100 million up...
...ZFP) therapeutics targeting four genes -- Factors VII, VIII, IX and X. Seaview Securities advised FerroKin...
Items per page:
1 - 10 of 14